Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics

Aims: Patients with familial hypercholesterolemia (FH) are known to have higher exposure to coronary risk than those without FH with similar low-density lipoprotein cholesterol (LDL-C) level. Lipid-lowering medications (LLMs) are the mainstay treatments to lower the risk of premature coronary artery...

Full description

Bibliographic Details
Published in:Journal of Atherosclerosis and Thrombosis
Main Author: Chua Y.-A.; Nazli S.A.; Rosman A.; Kasim S.S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.M.; Nawawi H.
Format: Article
Language:English
Published: Japan Atherosclerosis Society 2023
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162056339&doi=10.5551%2fJAT.63389&partnerID=40&md5=833730496bf6a586e927124e395ae527
id 2-s2.0-85162056339
spelling 2-s2.0-85162056339
Chua Y.-A.; Nazli S.A.; Rosman A.; Kasim S.S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.M.; Nawawi H.
Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
2023
Journal of Atherosclerosis and Thrombosis
30
10
10.5551/JAT.63389
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162056339&doi=10.5551%2fJAT.63389&partnerID=40&md5=833730496bf6a586e927124e395ae527
Aims: Patients with familial hypercholesterolemia (FH) are known to have higher exposure to coronary risk than those without FH with similar low-density lipoprotein cholesterol (LDL-C) level. Lipid-lowering medications (LLMs) are the mainstay treatments to lower the risk of premature coronary artery disease in patients with hypercholesterolemia. However, the LLM prescription pattern and its effectiveness among Malaysian patients with FH are not yet reported. The aim of this study was to report the LLM prescribing pattern and its effectiveness in lowering LDL-C level among Malaysian patients with FH treated in specialist hospitals. Methods: Subjects were recruited from lipid and cardiac specialist hospitals. FH was clinically diagnosed using the Dutch Lipid Clinic Network Criteria. Patients’ medical history was recorded using a standardized questionnaire. LLM prescription history and baseline LDL-C were acquired from the hospitals’ database. Blood samples were acquired for the latest lipid profile assay. Results: A total of 206 patients with FH were recruited. Almost all of them were on LLMs (97.6%). Only 2.9% and 7.8% of the patients achieved the target LDL-C of <1.4 and <1.8 mmol/L, respectively. The majority of patients who achieved the target LDL-C were prescribed with statin–ezetimibe combination medications and high-intensity or moderate-intensity statins. All patients who were prescribed with ezetimibe monotherapy did not achieve the target LDL-C. Conclusion: The majority of Malaysian patients with FH received LLMs, but only a small fraction achieved the therapeutic target LDL-C level. Further investigation has to be conducted to identify the cause of the suboptimal treatment target attainment, be it the factors of patients or the prescription practice. © 2023 Japan Atherosclerosis Society.
Japan Atherosclerosis Society
13403478
English
Article
All Open Access; Gold Open Access
author Chua Y.-A.; Nazli S.A.; Rosman A.; Kasim S.S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.M.; Nawawi H.
spellingShingle Chua Y.-A.; Nazli S.A.; Rosman A.; Kasim S.S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.M.; Nawawi H.
Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
author_facet Chua Y.-A.; Nazli S.A.; Rosman A.; Kasim S.S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.M.; Nawawi H.
author_sort Chua Y.-A.; Nazli S.A.; Rosman A.; Kasim S.S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.M.; Nawawi H.
title Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
title_short Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
title_full Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
title_fullStr Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
title_full_unstemmed Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
title_sort Attainment of Low-Density Lipoprotein Cholesterol Targets and Prescribing Pattern of Lipid-Lowering Medications among Patients with Familial Hypercholesterolemia Attending Specialist Clinics
publishDate 2023
container_title Journal of Atherosclerosis and Thrombosis
container_volume 30
container_issue 10
doi_str_mv 10.5551/JAT.63389
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162056339&doi=10.5551%2fJAT.63389&partnerID=40&md5=833730496bf6a586e927124e395ae527
description Aims: Patients with familial hypercholesterolemia (FH) are known to have higher exposure to coronary risk than those without FH with similar low-density lipoprotein cholesterol (LDL-C) level. Lipid-lowering medications (LLMs) are the mainstay treatments to lower the risk of premature coronary artery disease in patients with hypercholesterolemia. However, the LLM prescription pattern and its effectiveness among Malaysian patients with FH are not yet reported. The aim of this study was to report the LLM prescribing pattern and its effectiveness in lowering LDL-C level among Malaysian patients with FH treated in specialist hospitals. Methods: Subjects were recruited from lipid and cardiac specialist hospitals. FH was clinically diagnosed using the Dutch Lipid Clinic Network Criteria. Patients’ medical history was recorded using a standardized questionnaire. LLM prescription history and baseline LDL-C were acquired from the hospitals’ database. Blood samples were acquired for the latest lipid profile assay. Results: A total of 206 patients with FH were recruited. Almost all of them were on LLMs (97.6%). Only 2.9% and 7.8% of the patients achieved the target LDL-C of <1.4 and <1.8 mmol/L, respectively. The majority of patients who achieved the target LDL-C were prescribed with statin–ezetimibe combination medications and high-intensity or moderate-intensity statins. All patients who were prescribed with ezetimibe monotherapy did not achieve the target LDL-C. Conclusion: The majority of Malaysian patients with FH received LLMs, but only a small fraction achieved the therapeutic target LDL-C level. Further investigation has to be conducted to identify the cause of the suboptimal treatment target attainment, be it the factors of patients or the prescription practice. © 2023 Japan Atherosclerosis Society.
publisher Japan Atherosclerosis Society
issn 13403478
language English
format Article
accesstype All Open Access; Gold Open Access
record_format scopus
collection Scopus
_version_ 1809678022099337216